BACKGROUND: In gastric cancer, the recurrence rate is high even after curative surgery. A relevant issue is the identification of independent prognostic factors to select high-risk patients; such features can be used as predictive factors for tailored therapies. In this study we have investigated the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for predicting cancer behavior and clinical outcome in gastric cancer patients undergoing potentially curative surgery. METHODS: Epidermal growth factor receptor determination using a commercially available immunohistochemistry (IHC) kit was performed in tissues from 82 gastric cancer patients receiving primary surgical treatment and in 25 normal gastric mucosa specimens from noncancer patients. The EGFR positivity was correlated with disease recurrence and survival in univariate and multivariate analyses. RESULTS: Forty-four percent (36 cases) of gastric cancers were EGFR positive. In 66 curatively treated patients, EGFR expression correlated with disease recurrence and poorer survival in both univariate and multivariate analyses. In a multivariate model for predicting recurrence and survival, advanced tumor extension (T(3) or T(4)), nodal metastases, and EGFR expression were the only independent covariates. In particular, EGFR expression was shown to be a significant predictor of poor prognosis among gastric cancer patients having the same stage according to the current TNM staging system. CONCLUSIONS: These findings suggest that EGFR expression may be useful in identifying high-risk gastric cancer patients undergoing potentially curative surgery. Multimodal treatments should be considered in the adjuvant treatment of these patients.
BACKGROUND: In gastric cancer, the recurrence rate is high even after curative surgery. A relevant issue is the identification of independent prognostic factors to select high-risk patients; such features can be used as predictive factors for tailored therapies. In this study we have investigated the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for predicting cancer behavior and clinical outcome in gastric cancerpatients undergoing potentially curative surgery. METHODS:Epidermal growth factor receptor determination using a commercially available immunohistochemistry (IHC) kit was performed in tissues from 82 gastric cancerpatients receiving primary surgical treatment and in 25 normal gastric mucosa specimens from noncancer patients. The EGFR positivity was correlated with disease recurrence and survival in univariate and multivariate analyses. RESULTS: Forty-four percent (36 cases) of gastric cancers were EGFR positive. In 66 curatively treated patients, EGFR expression correlated with disease recurrence and poorer survival in both univariate and multivariate analyses. In a multivariate model for predicting recurrence and survival, advanced tumor extension (T(3) or T(4)), nodal metastases, and EGFR expression were the only independent covariates. In particular, EGFR expression was shown to be a significant predictor of poor prognosis among gastric cancerpatients having the same stage according to the current TNM staging system. CONCLUSIONS: These findings suggest that EGFR expression may be useful in identifying high-risk gastric cancerpatients undergoing potentially curative surgery. Multimodal treatments should be considered in the adjuvant treatment of these patients.
Authors: J Sanz-Ortega; S M Steinberg; E Moro; M Saez; J A Lopez; E Sierra; J Sanz-Esponera; M J Merino Journal: Histol Histopathol Date: 2000-04 Impact factor: 2.303
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Gennaro Galizia; Eva Lieto; Francesca Ferraraccio; Ferdinando De Vita; Paolo Castellano; Michele Orditura; Vincenzo Imperatore; Anna La Mura; Giovanni La Manna; Margherita Pinto; Giuseppe Catalano; Carlo Pignatelli; Fortunato Ciardiello Journal: Ann Surg Oncol Date: 2006-04-18 Impact factor: 5.344
Authors: Gennaro Galizia; Francesca Ferraraccio; Eva Lieto; Michele Orditura; Paolo Castellano; Vincenzo Imperatore; Giovanni La Manna; Margherita Pinto; Fortunato Ciardiello; Anna La Mura; Ferdinando De Vita Journal: J Surg Oncol Date: 2006-03-01 Impact factor: 3.454
Authors: Reinhard Kopp; Elisabeth Rothbauer; Maximilian Ruge; Hans Arnholdt; Joachim Spranger; M Muders; Doris G Pfeiffer; Friedrich Wilhelm Schildberg; Andreas Pfeiffer Journal: Recent Results Cancer Res Date: 2003
Authors: Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel Journal: Mol Pharm Date: 2016-10-10 Impact factor: 4.939
Authors: J-S Kim; M-A Kim; T M Kim; S-H Lee; D-W Kim; S-A Im; T-Y Kim; W H Kim; H-K Yang; D S Heo; Y-J Bang; K-U Lee; K-J Choe; N K Kim Journal: Br J Cancer Date: 2009-03-10 Impact factor: 7.640